Novartis’ Xolair backed in global urticaria guidelines
Novartis’ Xolair has been recommended in global guidelines for treating chronic spontaneous urticaria in patients unresponsive to antihistamines.
Read More
Tag: urticaria
- KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
- Pepaxti study supports use in wider myeloma population
- UCB reports positive outcomes for bimekizumab in psoriatic arthritis
- AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
- Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies
